Search clinical trials for: Placebo Liquid Auto-injector

Total 2646 results

GlaxoSmithKline

Completed

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Diabetes Mellitus, Type 2

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
University of Washington
Novo Nordisk A/S

Not yet recruiting

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

Diabetes Mellitus, Type 2 | Stroke (CVA) or Transient Ischemic Attack

United States
Centocor, Inc.
Quintiles, Inc.

Completed

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

Rheumatoid Arthritis | Psoriasis | Psoriatic Arthritis | Ankylosing Spondylitis

United States
Imperial College Healthcare NHS Trust
Imperial College London

Active, not recruiting

Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1) (EVOCAR-1)

Carotid Artery Stenosis

United Kingdom
Eli Lilly and Company

Completed

A Device Study in Healthy Participants

Healthy

United Kingdom
University of Pennsylvania
Novartis

Recruiting

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Psoriasis

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

Mepolizumab in the Treatment of Patients With Severe Uncontrolled CRSwNP: a Multicentric Real Life Observational Study (MEPOREAL)

Chronic Rhinosinusitis With Nasal Polyps

Italy
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (MATURE)

Plaque Psoriasis

Spain, Germany, United States, Iceland, Canada, Poland
UMC Utrecht
Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Unknown

Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia (EVOLVE-FD)

Hyperlipoproteinemia Type III | Familial Dysbetalipoproteinemia
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Eczema, Atopic | Atopic Disorders

United States
Hoffmann-La Roche

Completed

A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers

Healthy Volunteer

France
National Institute of Allergy and Infectious Diseases...

Withdrawn

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

Influenza

United States
University of New Mexico

Completed

Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

Lichen Planus | Lichen Planopilaris | Lichen Planus Scalp

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Hypercholesterolaemia

United States
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-M)

Diabetes Mellitus, Type 2

United States, Canada, Romania, Russian Federation, Ukraine, Germany, Spain, Philippines, Czech Republic, Mexico, Croatia, Chile, Morocco, South Africa, Australia, Venezuela
Hospices Civils de Lyon
GlaxoSmithKline

Recruiting

Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices (SECURE)

Asthma

France
Tulane University
Louisiana State University Health Sciences Center in New Orleans; Antares Pharma...

Not yet recruiting

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

Multiple Sclerosis | Erectile Dysfunction | Testosterone Deficiency

United States
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, India, Belgium, Mexico, Tunisia, Japan, Israel, Korea, Republic of
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (GETGOAL-S)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Germany, Netherlands, Turkey, Bulgaria, India, Taiwan, Czech Republic, Tunisia, Japan, Egypt, Israel, Korea, Republic of, Thailand
Lisata Therapeutics, Inc.

Completed

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina (RENEW)

Refractory Angina Pectoris | Chronic Myocardial Ischemia | Advanced Coronary Heart Disease

United States
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-F1)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Romania, Ukraine, Germany, Italy, Estonia, Malaysia, Philippines, Mexico, Lithuania, Colombia, Slovakia, Chile
Sanofi

Completed

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (GetGoal-M-Asia)

Type 2 Diabetes Mellitus

China, Hong Kong, Malaysia, Thailand
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (GETGOAL-L)

Diabetes Mellitus, Type 2

United States, France, Canada, Brazil, Russian Federation, Germany, Italy, Turkey, India, Mexico, Egypt, United Kingdom, Korea, Republic of, Chile, Puerto Rico
Eli Lilly and Company

Completed

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis (UNCOVER-A)

Plaque Psoriasis

United States, Puerto Rico
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (GETGOAL-P)

Diabetes Mellitus Type 2

United States, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) (GETGOAL-L-ASIA)

Diabetes Mellitus, Type 2

Philippines, Taiwan, Japan, Korea, Republic of
Chang Gung Memorial Hospital

Unknown

A Preliminary Randomized Study of Tianjiu (Auto-moxibustion) Effects in Patients With Intradialytic Hypotension

Intradialytic Hypotension

Taiwan
Alto Neuroscience

Recruiting

Phase 2b Study of ALTO-100 in MDD

Major Depressive Disorder

United States
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS) (GETGOAL-MONO)

Diabetes Mellitus, Type 2

Japan
Alto Neuroscience

Recruiting

Study of ALTO-300 in MDD

Major Depressive Disorder

United States
Genentech, Inc.

Completed

A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants

Healthy Volunteer

United States
University Health Network, Toronto
GlaxoSmithKline

Not yet recruiting

Belimumab in Autoimmune Hepatitis (BELief)

Autoimmune Hepatitis
Eli Lilly and Company

Terminated

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Lupus Erythematosus, Systemic

Korea, Republic of, Puerto Rico, United States
Vivozon, Inc.

Completed

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.

Post-Operative Pain

Korea, Republic of
Geisinger Clinic

Terminated

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy (RAISE-KT)

Obesity | Diabetic Kidney Disease | Type 2 Diabetes Mellitus in Obese | CKD | Severe Obesity

United States
Peking University Third Hospital
Beijing Tiantan Hospital

Active, not recruiting

Clinical Evaluation of the Combination of Symptoms and Symptoms With General Treatment for Acute Hemorrhagic Stroke

Acute Hemorrhagic Stroke

China
GlaxoSmithKline

Terminated

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Diabetes Mellitus, Type 2

United States
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
Tongji Hospital

Unknown

Parathyroid Auto-transplantation: Prospective Randomized Trial of the Personalized Site

Parathyroid Autologous Transplantation

China
Microbiome Health Research Institute
Boston Medical Center

Completed

Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization (RACE)

Antibiotic Resistant Strain

United States
University of Washington
U.S. National Science Foundation

Completed

Naloxone Auto-injection in Healthy Volunteers

Overdose Antidote

United States
Sanofi

Completed

Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
University of New Mexico
Kaleo Inc.

Completed

Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder

Opioid-Related Disorders | Opiate Antagonist Overdose

United States
VIVEX Biologics, Inc.
MCRA

Withdrawn

Study of AlloGen® Liquid Intra-articular Injection for Knee Osteoarthritis

Osteoarthritis, Knee
Eli Lilly and Company

Completed

A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants

Healthy

Singapore
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-X)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Russian Federation, Germany, Italy, Netherlands, Spain, Sweden, Argentina, Denmark, Finland, Hungary, Norway, Colombia, Austria, Greece, Puerto Rico
Genentech, Inc.

Completed

A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

Healthy Volunteers

United States
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Acute Upper Respiratory Infections

Russian Federation
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more

Search clinical trials for: Placebo Liquid Auto-injector

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations